Brief: Stipple Bio Enters Multi-Target Oncology Collaboration With Eli Lilly
BRIEF-Stipple Bio Enters Multi-Target Oncology Collaboration With Eli Lilly Nov 16 (Reuters) - Eli Lilly and Company LLY.N:
STIPPLE BIO: ENTERS MULTI-TARGET ONCOLOGY COLLABORATION WITH ELI LILLY
STIPPLE BIO: WILL BE ELIGIBLE TO RECEIVE AGGREGATE PAYMENTS OF UP TO $5.9 BILLION DOLLARS UPON ACHIEVEMENT OF RESEARCH WITH LILLY
STIPPLE BIO: WILL RECEIVE AN UPFRONT PAYMENT AND AN EQUITY INVESTMENT UNDER TERMS OF LILLY AGREEMENT
STIPPLE BIO: LILLY RECEIVES EXCLUSIVE WORLDWIDE RIGHTS TO DEVELOP AND COMMERCIALIZE PRODUCTS ARISING FROM COLLABORATION
Source text: ID:nGNX8nZBX6
Further company coverage: LLY.N
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Eli Lilly and
See all newsBiogen's anti-tau Alzheimer's drug benefits increase at 2 years
Eli Lilly’s $1.4 trln valuation is heavy with hope
Lilly signs cancer research deal with Stipple Bio worth up to $5.9 billion (updated)
Brief: Stipple Bio Enters Multi-Target Oncology Collaboration With Eli Lilly
Deals of the day-Mergers and acquisitions